Office location

Urology - Third
8635 W Third St #1070W
Los Angeles


  • Urology

    Provider Info




    Korean, English


    25 years


    • UCLA David Geffen School of Medicine
      Fellowship - Completed 2004
    • UCLA David Geffen School of Medicine
      Fellowship - Completed 2003
    • University of Chicago Hospitals
      Residency - Completed 2002
    • University of Chicago Medical Center
      Internship - Completed 1998
    • University of Chicago Pritzker School of Medicine
      Medical School - Completed 1996


    Hyung L. Kim, MD, is director of the Cedars-Sinai Academic Urology Program and associate director of Surgical Research in the Samuel Oschin Comprehensive Cancer Center. He has two professional passions. As a practicing urologic oncologist, Kim is devoted to promoting the physical and emotional health of his patients with cancers of the kidney, testis, prostate and bladder. His training includes fellowships in urologic oncology and minimally invasive surgery. He routinely provides treatments and second opinions for complex and difficult urologic cancer cases. Kim's second area of professional passion is his laboratory research, which has two areas of focus. The first area involves developing novel immune therapies for cancers. His lab is investigating the immune modulating effects of molecularly targeted therapies administered in combination with cancer vaccines. Heat shock protein-based cancer vaccines are used as model vaccines. Therapeutic goals include generating high-quality memory T cells and suppressing regulatory T cells. Kim's research also focuses on discovery and validation of clinically useful biomarkers for patients with urologic cancers. His laboratory has been developing new technology for generating multimarker expression profiles using archival tumors. His clinical work and research are highly complementary. Kim can offer his patients leading-edge treatment approaches, and the most challenging patient cases provide ideas and inspiration for his research.


    • Li P, Conley A, Zhang H, Kim HL. Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq. BMC Genomics. 2014;15:1087.
    • Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, Teh BT, Kim HL. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859-864.
    • Kim HL, Puymon MR, Qin, M, Guru K, Mohler JL. A method for using life tables to estimate lifetime risk for prostate cancer death. J Natl Compr Canc Netw. 2010;8(2):148-154.
    • Underwood W, Kim HL. Intermediate-term oncological efficacy of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell testicular cancer. BJU Int. 2012;109(2):281-285.


    Board Certifications

    • Board Certified in Urology

    Awards & Activities

    • Edwin Beer Award
    • American Urologic Association Surgeon Scientist Award
    • Endowment, Medallion Chair in Urology
    • Cancer and Leukemia Group B Junior Faculty Research Award

    Patient Ratings & Comments Learn more


    Average Rating:
    4.9 / 5
    314 Ratings

    Rating Breakdown

    five star (303):
    four star (11):
    three star (0):
    two star (0):
    one star (0):


    By Cedars-Sinai Patienton Sep 15, 2021

    I have total confidence in Doctor Kim. He's very professional and treats me with respect each time I see him. Always a positive experience.

    By Cedars-Sinai Patienton Sep 08, 2021

    I am very pleased with Dr. L. Kim and his staff and nurses. Every visit I made, he was very professional, answered all my questions, put me at ease. I feel in very good hands. Thank you very much.

    By Cedars-Sinai Patienton Sep 08, 2021

    Dr. Kim and his staff are exceptionally the BEST. He saved my life seven years ago and I've been with him since then a doctor with compassion and understanding ,I'm so great full